

Amyloidosis Research Consortium: Research Roundtable

January 19th – 21st, 2024 Miami, FL

DAY 1: FRIDAY, JANUARY 19TH

7:00 am Breakfast (Marriott Bayfront Terrace South)

8:00 amRegistration Opens

Amyloidosis Research Roundtable Double Tree by Hilton Biscayne Bay, Grand Ballroom

8:30am WELCOME AND INTRODUCTION (25 minutes)

Isabelle Lousada, Ashutosh Wechalekar, Sarah Cairns-Smith, Kristen Hsu

Session 1 WHAT HAS CHANGED OVER THE PAST 5 YEARS?

8:55am Basic and Translational Research

Moderators: Jeff Kelly & Stefan Schoenland

Scientist's Perspective (20 minutes) Jeff Kelly

Clinician's perspective (20 minutes) Stefan Schoenland

Key Future Priorities (20 minutes) Basic/Translational Research Group Discussion

9:55 am Break (15 minutes)

10:10 am <u>AL Amyloidosis</u>

Moderator: Morie Gertz

Update on natural history (10 minutes)

Vaishali Sanchorawala

Approval and impact of daratumumab in AL (10 minutes)

Shaji Kumar

Progress of other therapeutic approaches (e.g., anti-amyloid, CART, biospecifics) (10 minutes)

Murielle Roussel

What challenges have now emerged/remain? The perspective of industry (10

minutes)

Jessica Vermeulen

Discussion/Q&A (20 minutes)

All



11:10 am ATTR Amyloidosis

Moderator: Mat Maurer

Update on natural history (10 minutes) Marianna Fontana, Tom Brannagan

New therapeutic options available, new trials ongoing (10 minutes) Rodney Falk

Better diagnosis and new treatments have changed the characteristics of the population (10 minutes) Paolo Milani

What challenges have now emerged/remain? Industry perspective (10 minutes) *Pushkal Garg*

Discussion (20 minutes)

12:10 pm Group Photo (25 minutes)

12:35 pmLunch (85 minutes - Marriott Bayfront Terrace South)

Session 2 ADVANCING THE SCIENCE OF CLINICAL TRIALS

2:00 pm AL Amyloidosis

Moderator: Morie Gertz

What are the lessons learned from recent clinical trials? (10 minutes) *Ray Comenzo*

What additional clinical trials are needed? (10 minutes) *Stathis Kastritis*

Development of a PRO/status of current PROs (10 minutes) Vaishali Sanchorawala, Anita D'Souza

Definition of progression (10 minutes) Angela Dispenzieri

Key future priorities (20 minutes) AL Group Discussion

3:00 pm Break (15 minutes)

3:15 pm Breakout Session Sneak Peeks

Basic/Translational Science: pathway for non-biopsy diagnosis (10 minutes) Stephan Harding, Gareth Morgan, Jon Wall

Development of a new staging system (10 minutes) Shaji Kumar, Ashutosh Wechalekar

3:35 pm <u>Hot Topic Discussion (25 minutes)</u> <u>Moderators:</u> Ashutosh Wechalekar & Sarah Cairns-Smith

4:00 pm Adjourn

6:15 pm Depart for Dinner



DAY 2: SATURDAY, JANUARY 20TH

7:00 amBreakfast (Marriot Bayfront Terrace South)

Amyloidosis Research Roundtable Miami Marriott Biscayne Bay, Watson Island

8:30 am Chairman Summary (10 minutes)

Ashutosh Wechalekar

Session 2 ADVANCING THE SCIENCE OF CLINICAL TRIALS (cont.)

8:40 am ATTR Amyloidosis

Moderator: Rodney Falk

What are the lessons learned from recent therapeutic clinical trials? (10 minutes) *Spencer Guthrie, Adam Castano*

How do we approach eye or CNS involvement? (10 minutes) *Jeff Kelly*

ATTR-PN and combination therapy (10 minutes) Sami Khella, Laura Obici

Status of PROs (10 minutes) Kristen Hsu, Michelle Carty

Key future priorities (20 minutes) ATTR Group Discussion

9:40 am Breakout Session Sneak Peeks

How do we diagnose early? (10 minutes) Marianna Fontana

9:50 am Break (15 minutes)

Session 3 IMPROVING CLINICAL CARE

Moderators: Ashutosh Wechalekar & Mat Maurer

10:05 am Focus on AL Amyloidosis

Improving management of stage 3b/4 AL patients (10 minutes) Vaishali Sanchorawala, Paolo Milani

Addressing the poor/non-responders to daratumumab in AL (10 minutes) Angela Dispenzieri, Stathis Kastritis

Key future priorities (15 minutes) AL Group Discussion

10:40 am Focus on ATTR Amyloidosis

PYP/DPD scans - Challenges? Accuracy? What do changes mean? (10 minutes)



Marianna Fontana

Prevention and when to start treatment? (10 minutes) Adam Castano

Increased numbers of patients managed at specialized centers (10 minutes) Renee Bullock-Palmer

Key future priorities (15 minutes) ATTR Group

11:25 am Measuring & Monitoring Disease

Use/potential of biomarkers (10 minutes) Rodney Falk, Jeff Kelly

How can we monitor amyloid load? (10 minutes) Marianna Fontana, Sharmila Dorbala, Cristina Quarta

How can we monitor disease progression/response to therapy? (10 minutes) Ray Comenzo, Laura Obici

Key future priorities (15 minutes) Measure & Monitor Discussion Group

12:10 pm What Matters to Patients?

What matters most to patients (10 minutes) Sabrina Rebello, Isabelle Lousada

Treatment and frailty of elderly patients, role of supportive care (10 minutes) Ashutosh Wechalekar, Sami Khella, Mat Maurer

Health Disparities, access (10 minutes) Renee Bullock-Palmer

Key future priorities (15 minutes) Patient Care Discussion Group

12:55 pmLunch (50 minutes - Bayfront Terrace South)

1:45 pm Breakout Session Sneak Peek

Federated Data Analytics: An approach to data sharing (10 minutes) James Signorovitch

Session 4 BREAKOUT SESSIONS

1:55 pm Setting the stage: Aims of the breakout sessions (5 minutes) Sarah Cairns-Smith

2:00 pm BREAKOUT SESSIONS: IDENTIFYING THE UNMET NEEDS AND KEY PRIORITIES (120 minutes)

- Basic and translational Science (Group Leader *Gareth Morgan*)
- Shortening the time to diagnosis (Group Leader *Mat Maurer*)
- Unified staging systems for AL (Group Leader Ashutosh Wechalekar)
- Imaging current challenges, future tools (Group Leader Sharmila Dorbala)
- Data sharing (including federated approach) (Group Leader James Signorovitch)



4:00 Adjourn

6:45 pm Depart for Dinner



DAY 3: SUNDAY, JANUARY 21ST

7:00 amBreakfast (Marriot Bayfront Terrace South)

Amyloidosis Research Roundtable Miami Marriott Biscayne Bay, Bayview Ballroom

8:00 am Welcome (5 minutes) Isabelle Lousada

8:05 am A look back in history and forward into the future (15 minutes) Giampaolo Merlini

Session 5

KEY PRIORITIES

- 8:20 am AL Amyloidosis: Advancing the Science of Clinical Trials (10 minutes) Morie Gertz
- 8:30 am ATTR Amyloidosis: Advancing the Science of Clinical Trials (10 minutes) Rodney Falk
- 8:40 am Improving Clinical Care: AL and ATTR Amyloidosis, Measuring & Monitoring Disease, What Matters to Patients? (25 minutes) Ashutosh Wechalekar & Mat Maurer
- 9:05 am Recommendations of Breakout Sessions (Presentations 10 minutes, Discussion 15 minutes)

Open meeting

- 11:05 am Summary: What have I heard? (20 minutes) Preston Dunnmon, Morie Gertz
- 11:25 am Meeting Close (5 minutes)

Isabelle Lousada

11:30 am Coffee/Lunch/End of Meeting